BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192

Benzinga Newsdesk www.benzinga.com Positive 55.8%

Neg 0% Neu 0% Pos 55.8%

BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ:INSM) with a Outperform rating and announces Price Target of $192.